Introduction

Colombia is an important pharmaceutical market in Latin America, but introducing and maintaining a medicine requires careful attention to national regulatory requirements. Companies must understand the role of the National Food and Drug Surveillance Institute (INVIMA), prepare appropriate registration documentation, and establish systems to monitor product safety after market entry.

Regulatory compliance extends beyond obtaining a sanitary registration. It includes maintaining accurate product information, assessing safety signals, managing post-approval changes, and ensuring that product claims remain consistent with approved information. Integrating regulatory affairs and pharmacovigilance helps companies protect patients while maintaining oversight throughout a product’s lifecycle.

1. Understanding Colombia’s Regulatory Framework

INVIMA oversees the sanitary surveillance of medicines and biological products in Colombia. Its responsibilities include evaluating registration applications and monitoring product safety after authorisation. Companies should identify the rules that apply to their product category before planning a submission.

For medicines, the registration pathway and supporting evidence depend on factors such as product composition, classification, manufacturing details, and applicable technical requirements. Teams should consult current INVIMA guidance rather than assume that requirements for one category automatically apply to another.

An effective regulatory plan should identify:

• The applicable sanitary registration pathway.
• Required quality, safety, and efficacy documentation.
• Local representation and applicant responsibilities, where applicable.
• Product information and packaging requirements.
• Post-approval obligations and renewal timelines.

Companies assessing country-specific requirements can review Regulatory Affairs Services in Colombia as part of their broader market-entry planning.

2. Preparing for Sanitary Registration

A sanitary registration application requires accurate, consistent documentation. Regulatory teams should coordinate information from quality, manufacturing, clinical, medical, and safety functions to reduce discrepancies and avoid preventable follow-up questions.

Before submitting an application, teams should verify that the dossier aligns with the applicable INVIMA requirements. This includes checking product specifications, manufacturing information, proposed indications, dosage instructions, contraindications, and supporting evidence.

Practical preparation steps include:

• Confirming that the product classification and registration route are appropriate.
• Reviewing the completeness and consistency of technical documents.
• Checking that product information reflects the proposed authorised use.
• Establishing document version control and approval responsibilities.
• Tracking authority questions, responses, and submission milestones.

The sanitary registration process should also be considered alongside launch readiness. Importation, packaging, distribution, and local supply arrangements may involve additional requirements that should be assessed separately. INVIMA’s official medicines registration resources provide a starting point for reviewing applicable information.

3. Pharmacovigilance After Market Entry

Pharmacovigilance is a continuing responsibility after a medicine reaches patients. It supports the detection, assessment, understanding, and prevention of adverse effects and other medicine-related problems.

In Colombia, INVIMA’s National Pharmacovigilance Program provides mechanisms for collecting and evaluating safety information. Resolution 2024015321 of 2024 sets requirements concerning pharmacovigilance programmes and adverse-event reporting by relevant registration holders and manufacturers; it became effective on March 1, 2025. Companies should consult the current resolution and official implementation guidance to confirm the obligations applicable to their products.

A robust local process should cover:

• Receiving and documenting suspected adverse reaction reports.
• Assessing case seriousness and reportability.
• Submitting reports through the applicable reporting channel and timeline.
• Reviewing scientific literature and relevant international safety alerts.
• Detecting and evaluating potential safety signals.
• Maintaining traceable records and escalating significant safety concerns.

INVIMA identifies eReporting Industria as a reporting mechanism for relevant industry safety cases. Reporting requirements and periodic submissions should be checked against the applicable rules rather than inferred from general international practice.

For companies reviewing their local drug-safety processes, Pharmacovigilance Services in Colombia is a relevant resource for understanding the scope of country-specific pharmacovigilance activities.

4. Product Labeling and Claims Compliance

Product information helps healthcare professionals and patients understand a medicine’s approved use, dosage, precautions, and potential risks. Inconsistent labeling can create compliance concerns and contribute to medication errors.

Regulatory teams should verify that the product’s approved information, packaging components, and related materials remain aligned. Any proposed update should be assessed under the applicable change-control and approval requirements before implementation.

Key review areas include:

• Indications, dosage, contraindications, and warnings.
• Storage conditions, shelf life, and product identification.
• Consistency across packaging components and product documents.
• Translation accuracy and legibility, where relevant.
• Alignment of promotional claims with approved indications and supporting evidence.

Product Labeling Services may be relevant when reviewing labeling processes, while Claim Substantiation Services relates to evaluating whether product claims are adequately supported. In Colombia, teams should also verify the specific rules governing medicine advertising and promotional materials. Claims should not exaggerate benefits, minimise risks, or extend beyond the product’s authorised conditions of use.

5. Managing Lifecycle Responsibilities

Regulatory oversight continues as products change. Updated safety evidence, manufacturing changes, revised product information, and new regulatory requirements may trigger an assessment of whether a submission or other action is necessary.

A lifecycle management process should include a central tracker for registration status, commitments, variations, safety actions, and renewal dates. Regulatory, quality, medical, and pharmacovigilance teams should share relevant information so that changes are evaluated consistently.

Practical compliance checklist

• Confirm current registration status and upcoming deadlines.
• Maintain controlled, approved product information.
• Document safety-reporting procedures and responsibilities.
• Review applicable regulatory alerts and safety communications.
• Assess changes before implementation.
• Retain evidence of submissions, decisions, and completed actions.

Why Choose DDReg as your Consulting Partner

For teams planning market entry or reviewing compliance processes, Life Science Consulting Services can provide a starting point for exploring wider life-sciences regulatory topics. Regulatory Intelligence Tools may support monitoring of relevant regulatory developments, while Regulatory Affairs Lifecycle Management is relevant to organising ongoing submissions, commitments, and post-approval activities.

Conclusion

Regulatory affairs and pharmacovigilance in Colombia require coordinated management of registration, product information, safety reporting, and post-approval changes. Companies can strengthen compliance by assigning clear responsibilities, maintaining reliable documentation, and routinely checking current INVIMA requirements.

A lifecycle-based approach helps regulatory teams respond to changing evidence and obligations while keeping patient safety central to product management.